Sage Journals: Discover world-class research

Abstract

Objective

To establish whether the clinical effect of neutralizing antibodies (NAbs) against interferon-beta (IFNβ) depends on the type of IFNβ (1a or 1b) used for treatment of patients with relapsing-remitting multiple sclerosis (MS).

Introduction

NAbs against IFNβ-1b appear faster and may be more evenly distributed on IgG subclasses, whereas NAbs against IFNβ-1a develop more slowly and may be devoid of IgG3. This might cause different clinical responses to NAbs.

Design/patients

All Danish MS-patients who had started first-time treatment with IFNβ-1a 22 μg s.c tiw (Rebif22) or IFNβ-1b 250 μg s.c. qod (Betaferon) before January 1st 2003 were included. Relapses were recorded at bi-annual visit.

Methods

We measured NAbs every 12 months using a clinically validated cytopathic effect assay. A blood sample with a neutralizing capacity of 20% or more was considered as NAb-positive. We used a mixed logistic regression analysis in which NAb-status (three levels), IFNβ-preparation, and time since treatment started were included as explanatory variables, and relapse rate as response variable.

Results

In 1,309 patients, who were observed for 21,958 months, 32.3% were classified as NAb-positive. The odds-ratio (OR) for relapses in NAb-positive months compared with NAb-negative months was 1.25; P = 0.02. The risk of relapses was higher with Betaferon than with Rebif22 (OR 1.26; P < 0.01). The effect of NAb-level on relapses was independent of whether the patients were treated with Betaferon or Rebif22 (P = 0.89) and of time (P = 0.80).

Conclusion

NAbs caused by IFNβ-1a s.c. do not differ from NAbs caused by IFNβ-1b in their detrimental clinical effect.

Keywords

interferon-beta interferon-beta antibodies multiple sclerosis neutralizing antibodies therapy treatment effect

Get full access to this article

View all access options for this article.

References

1 Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group [see comments]. Neurology 1993; 43: 655–661.

2 Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group [see comments]. Neurology 1996; 47: 889–894.

3 Sorensen PS Ross C Clemmesen KM . Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 2003; 362: 1184–1191.

4 PRISMS-4 . Long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 2001; 56: 1628–1636.

5 Francis GS Rice GP Alsop JC . Interferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS. Neurology 2005; 65: 48–55.

6 Kappos L Clanet M Sandberg-Wollheim M . Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study. Neurology 2005; 65: 40–47.

7 Goodin DS Hurwitz B Noronha A . Neutralizing antibodies to interferon beta-1b are not associated with disease worsening in multiple sclerosis. J Int Med Res 2007; 35: 173–187.

8 Bertolotto A Malucchi S Milano E Castello A Capobianco M Mutani R . Interferon beta neutralizing antibodies in multiple sclerosis: neutralizing activity and cross-reactivity with three different preparations. Immunopharmacology 2000; 48: 95–100.

9 Sominanda A Hillert J Fogdell-Hahn A . In vivo bioactivity of interferon-beta in multiple sclerosis patients with neutralising antibodies is titre-dependent. J Neurol Neurosurg Psychiatry 2008; 79: 57–62.

10.

10 Sominanda A Rot U Suoniemi M Deisenhammer F Hillert J Fogdell-Hahn A . Interferon beta preparations for the treatment of multiple sclerosis patients differ in neutralizing antibody seroprevalence and immunogenicity. Mult Scler 2007; 13: 208–214.

11.

11 Gibbs E Oger J . The IgG subclass-specificities of anti-IFNbeta antibodies change with time and differ between the IFNbeta products in relapsing remitting multiple sclerosis patients. J Neuroimmunol 2007; 190: 146–150.

12.

12 Koch-Henriksen N Sorensen PS ; The Danish Multiple Sclerosis Group. The Danish National Project of interferon-beta treatment in relapsing-remitting multiple sclerosis. Mult Scler 2000; 6: 172–175.

13.

13 Sorensen PS Koch-Henriksen N Ross C Clemmesen KM Bendtzen K . Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology 2005; 65: 33–39.

14.

14 Schumacher GA Beebe G Kibler RF . Problems of experimental trials of therapy in multiple sclerosis: report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis. Ann N Y Acad Sci 1965; 122: 552–568.

15.

15 Bendtzen K . Anti-IFN BAb and NAb antibodies: a minireview. Neurology 2003; 61: S6–S10.

16.

16 Hesse D Sorensen PS . Using measurements of neutralizing antibodies: the challenge of IFN-beta therapy. Eur J Neurol 2007; 14: 850–859.

17.

17 Sorensen PS Tscherning T Mathiesen HK . Neutralizing antibodies hamper IFNbeta bioactivity and treatment effect on MRI in patients with MS. Neurology 2006; 67: 1681–1683.

18.

18 Gneiss C Tripp P Reichartseder F . Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patients. Mult Scler 2006; 12: 731–737.

19.

19 Sorensen, PS, Koch-Henriksen, N, Bendtzen, K. Is treatment effect of IFN-beta restored after disappearance of neutralizing antibodies? Mult Scler 2008; 14: 837–842.

The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis

Abstract

Keywords

Get full access to this article

References